News FDA experts back Novo Nordisk's key diabetes drug Novo hopes for blockbuster sales from semaglutide
News Lilly joins cancer vaccine race with CureVac alliance Lilly has signed a deal with CureVac to develop up to five next-generation cancer vaccines which use messenger RNA (mRNA) technology.
News J&J hopes FDA cardio label will limit Invokana damage Diabetes drug has been hit by amputation warning on label.
News Lilly’s Verzenio joins breast cancer market The FDA has approved Lilly’s Verzenio, making it the third market entrant in a new class of drugs for breast cancer.
News More data supports Jardiance lead in cardiovascular battle Cardioprotective effect occurred in patients independently of blood sugar control
News Novo's semaglutide outperforms Lilly GLP-1 rival If approved semaglutide could become set the standard for GLP-1 therapy
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
